tricin

Tricin can inhibit human cytomegalovirus (HCMV) replication by inhibiting CDK9. Tricin inhibits the proliferation and invasion of C6 glioma cells via the upregulation of focal-adhesion-finase (FAK)-targeting microRNA-7.

Tricin 7-O-glucuronide is a flavonoid from Alfalfa (Medicago sativa L.).

Tricin 7-O-glucoside is a naturally occurring flavonoid with antidepressant and anxiolytic properties that increases the activity time of mice in the forced swim test. It protects the brain by attenuating brain I/R damage and attenuating blood-brain barrier (BBB) disruption, decreasing HMGB1 and NF-κB signaling pathways.

Tricin (Standard) is a reference standard for research and analysis in studies involving Tricin. Tricin can inhibit human cytomegalovirus (HCMV) replication by inhibiting CDK9. Tricin inhibits the proliferation and invasion of C6 glioma cells via the upregulation of focal-adhesion-finase (FAK)-targeting microRNA-7.

Tricin 5-gucoside is a reagent used in biochemical reactions.

Tricine is an amphoteric ion biological buffer agent with an effective buffering range of pH 7.4 to 8.8, commonly used in the Tricine-SDS-PAGE system.

6-Methoxytricin, a flavonoid isolated from Centella asiatica, is an inhibitor of aldose reductase (AR) and advanced glycosylation end-products (AGE), and inhibits T-cell proliferation and activation in biologic cells.

Mepartricin, a polyene macrolide, exhibits both antifungal and antiprotozoal activities and is extensively utilized in studies related to benign prostatic hyperplasia.

Valinotricin is a minor fungal metabolite.

Amcipatricin diaspartate (SPA-S-753), a semi-synthetic polyene antibiotic, exhibits potent broad-spectrum antifungal activity [1].

Matricin is a glycoside that can be isolated from Mexican herbs.

GIP (3-42), human (Gastric Inhibitory Polypeptide (3-42) (human)) is a peptide that acts as a glucose-dependent proinsulinotropic polypeptide (GIP) receptor antagonist and regulates insulin secretion and the metabolic effects of GIP in vivo, which can be used to study type 2 diabetes.

[Tyr0] Gastric Inhibitory Peptide (23-42), human, is a glucose-dependent insulinotropic polypeptide (GIP) that modestly inhibits gastric acid secretion while enhancing insulin secretion, making it relevant for research on diabetes and obesity [1] [2].

Gastric Inhibitory Polypeptide (1-30), porcine, deficient in the 12 C-terminal amino acids of the natural gastric inhibitory polypeptide (GIP), demonstrates biological activity by enhancing the release of insulin and somatostatin [1].

Gastric Inhibitory Peptide (porcine), also known as a glucose-dependent insulinotropic polypeptide, is a 42-amino acid intestinal hormone that influences fat and glucose metabolism [1].

Acetyl Gastric Inhibitory Peptide (human), a fatty acid-derivatized analog of glucose-dependent insulinotropic polypeptide, exhibits enhanced antihyperglycemic and insulinotropic characteristics. This compound is utilized in diabetes, insulin resistance, and obesity research [1] [2] [3].

(Pro3) GIP, human acetate (299898-52-5 Free base) is a potent, stable, and specific full agonist peptide for the human GIP receptor (GIPR). (Pro3) GIP, human acetate (299898-52-5 Free base) is the acetate salt form of a modified analog of natural GIP in which three alanine (Ala) residues have been mutated to proline (Pro). (Pro3) GIP, human acetate (299898-52-5 Free base) is a glucose-dependent insulin secretion (GIP) agonist and a weak inhibitor of gastric acid secretion.

Acetyl Gastric Inhibitory Peptide (human) TFA, a fatty acid-derivatized analog of the glucose-dependent insulinotropic polypeptide, exhibits enhanced antihyperglycemic and insulinotropic properties. It is utilized in the research of diabetes, insulin resistance, and obesity [1] [2] [3].

Gastric Inhibitory Polypeptide (6-30) amide (human) is an incretin hormone used in diabetes research [1].

Gastric Inhibitory Peptide (1-42) (porcine) TFA is a glucose-dependent insulinotropic polypeptide released by intestinal K-cells. It stimulates insulin secretion while inhibiting gastric acid secretion and gastrointestinal motility, thereby regulating digestive function.

Gastric inhibitory peptide 1 (GIP-1) (3-42), a fragment of the incretin hormone GIP and antagonist to the GIP receptor, is generated through the action of serum dipeptidyl peptidase 4 (DDP-4). When administered at 25 nmol/kg to an ob/ob mouse diabetes model, GIP-1 (3-42) elevates plasma glucose levels and lowers plasma insulin levels, demonstrating its effect on reducing insulin secretion from BRIN-BD11 pancreatic cells at a concentration of 100 nM.

Gastric inhibitory peptide (GIP) (22-51), a pro-atherogenic peptide comprised of 30 amino acids from the residues 22-51 of its precursor protein proGIP, is present in human plasma. It activates the degradation of IκB-α and the nuclear translocation of NF-κB in both macrophage-differentiated THP-1 cells and human aortic endothelial cells at a concentration of 1 µM. Additionally, in ApoE-/- mice, GIP (22-51) escalates the area of atherosclerotic lesions and plaque development in vivo.